首页> 外文期刊>Liver international : >MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma
【24h】

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma

机译:肝癌发生的MicroRNA分析将C19MC簇识别为肝细胞癌的新型预后生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and aims: Progressive hepatocarcinogenesis is a stepwise process that drives liver transformation. However, the molecular mechanisms of early liver transformation are far from clear. A role for microRNAs (miRNA) as diagnostic and prognostic factors in human tumours, including hepatocellular carcinoma (HCC), is promising. We aimed to identify novel miRNA as biomarkers for differential diagnosis and predictors of disease progression. Methods: We used a low-density array platform to profile the expression of 664 mature miRNA in a cohort of 60 hepatitis C virus-positive liver lesions representative of all stages of progressive hepatocarcinogenesis. We validated selected miRNA in two independent patient series by qPCR and we characterized the genomic status of the miRNA cluster C19MC by fluorescent in situ hybridization and copy-number variation analyses. Results: A 18-miRNA signature distinguished cirrhosis, dysplastic nodules and HCC lesions. Four miRNAs overexpressed in HCCs belonged to chromosome 19 miRNA cluster (C19MC). Significant overexpression of C19MC in early HCC compared to dysplastic nodules could be confirmed in a second series of hepatitis B virus-related liver lesions (n = 30). In a third series of 61 HCCs, C19MC cluster was overexpressed in HCCs compared to matched cirrhotic parenchyma and regardless of the type of viral infection. High C19MC miRNA levels were correlated with poor clinico-pathological features, increased risk of tumour recurrence and shorter overall survival time. HCCs overexpressing the C19MC cluster showed genetic amplification of the corresponding locus. Conclusions: C19MC cluster is a novel molecular alteration characteristic of liver cancer and predictor of poor prognosis. C19MC is an attractive candidate for novel HCC therapies.
机译:背景和目的:进行性肝癌发生是一个逐步的过程,可驱动肝脏转化。但是,早期肝转化的分子机制尚不清楚。 microRNA(miRNA)作为人类肿瘤(包括肝细胞癌(HCC))的诊断和预后因素的作用很有希望。我们旨在鉴定新型miRNA作为生物标志物,以进行差异诊断和疾病进展的预测指标。方法:我们使用低密度阵列平台分析了664个成熟miRNA在一组60例丙型肝炎病毒阳性肝病变中的表达情况,这些病变代表了进行性肝癌进展的所有阶段。我们通过qPCR验证了两个独立患者系列中的选定miRNA,并通过荧光原位杂交和拷贝数变异分析表征了miRNA簇C19MC的基因组状态。结果:18-miRNA标志物可区分出肝硬化,增生性结节和HCC病变。在肝癌中过表达的四个miRNA属于19号染色体miRNA簇(C19MC)。与第二批乙型肝炎病毒相关的肝损伤相比,在肝癌早期,C19MC与增生性结节相比明显过表达(n = 30)。在第三批61例HCC中,与匹配的肝硬化实质相比,C19MC簇在HCC中过表达,而与病毒感染的类型无关。高C19MC miRNA水平与不良的临床病理特征,增加的肿瘤复发风险和更短的总生存时间相关。过度表达C19MC簇的HCC显示相应基因座的遗传扩增。结论:C19MC簇是肝癌的一种新型分子改变特征,预后不良。 C19MC是新型HCC治疗的有吸引力的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号